Telix Pharmaceuticals Limited
NASDAQRecent
price
P/E
ratio
div
yld
- -
ROIC.AI
Capital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- Similar Companies
- Business
- Telix Pharmaceuticals Limited operates as a commercial-stage biopharmaceutical firm dedicated to advancing and delivering innovative therapeutic and diagnostic radiopharmaceutical agents. The company strategically focuses on a theranostic approach, combining imaging and treatment to precisely target cancers and certain rare conditions. Headquartered in North Melbourne, Australia, Telix maintains significant global operations across the United States, Europe, and Japan. Among its commercial offerings is Illuccix® (gallium-68 gozetotide injection), a key imaging agent utilized for detecting prostate-specific membrane antigen (PSMA)-positive lesions in prostate cancer. Illuccix has secured marketing authorizations in major territories including the United States, Australia, Canada, the United Kingdom, and across Europe. Another recently approved prostate cancer imaging agent, Gozellix®, has commenced its commercial launch in the U.S. Additionally, Telix provides Scintimun® (technetium-99m besilesomab) for imaging osteomyelitis in numerous European countries and Mexico, along with the SENSEI® surgical gamma probe for guided surgery. The company’s robust pipeline includes several late-stage investigational candidates. TLX591, a radio antibody-drug conjugate, is undergoing a pivotal Phase 3 clinical trial for metastatic castration-resistant prostate cancer. For renal (kidney) cancer, the diagnostic agent TLX250-CDx (Zircaix®) received a Complete Response Letter from the U.S. FDA, citing Chemistry, Manufacturing, and Controls deficiencies, despite its prior Breakthrough Therapy designation. TLX250 is being developed as a therapeutic counterpart for kidney cancer. Other significant candidates include TLX101-CDx for brain (glioma) cancer imaging and TLX101 for glioblastoma therapy, alongside TLX592 for targeted alpha therapy in prostate cancer, and TLX090 for metastatic bone pain. Telix also continues to expand its pipeline with novel fibroblast activation protein (FAP)-targeting theranostic agents, initially focusing on bladder cancer. Telix Pharmaceuticals reported strong financial performance in FY2024 with total revenue reaching $783.2 million AUD, predominantly driven by Illuccix sales, and projects FY2025 revenue guidance between $1.18 billion to $1.23 billion AUD ($770 million to $800 million USD). The company, founded in 2015, is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Company News
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
Telix Appoints David Gill as Chair
Telix Pharmaceuticals: Execution Is The Name Of The Game Here
Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript
Telix Pharmaceuticals H1 Earnings Call Highlights
Telix 2026 Half-Year Results: Strong Commercial Execution and Momentum in Late-Stage Pipeline
Telix to Host R&D Day in New York City on September 22, 2026
Telix Pharmaceuticals: The Radiopharma Operating System Is The Real Moat
Telix H1 2026 Results: Investor Webcast Notification
Does Telix Pharmaceuticals Limited (TLX) Have the Potential to Rally 86.17% as Wall Street Analysts Expect?
TLX591-Tx ProstACT SELECT Study Published in Cancers Journal
Telix Q2 Revenue US$247M, Strong Momentum and Pipeline Progress
Telix Doses First Patient in Phase 3 LUTEON Trial of TLX250-Tx for Renal Cancer
First Patients Dosed in OPTIMAL-e Trial for Earlier Stage Prostate Cancer
FDA Alignment to Advance ProstACT Global Phase 3 Trial
Telix Pharmaceuticals Limited (TLX) Discusses Neurologic Oncology Portfolio and Advances in Therapeutic and Diagnostic Agents Transcript
Telix Educational Webinar: Neuro-Oncology Portfolio Update and Physician Perspectives on Future Therapeutic Directions
Telix and United Imaging Announce Strategic Theranostics Collaboration
ProstACT Global Phase 3 (Part 1) Data Presented in Late-Breaking Oral Session at ASCO 2026
Telix to Participate in William Blair Growth Stock and Jefferies Global Healthcare Conferences